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People with Type 2 diabetes mellitus (T2DM) have reduced bone mineral density and an increased risk of
fractures due to altered mesenchymal stem cell (MSC) differentiation in the bone marrow. This leads to a
shift in the balance of differentiation away from bone formation (osteogenesis) in favour of fat cell
development (adipogenesis). The commonly used anti-diabetic drug, metformin, activates the osteogenic
transcription factor Runt-related transcription factor 2 (Runx2), which may suppress adipogenesis,
leading to improved bone health. Here we investigate the involvement of the metabolic enzyme, AMP-
activated protein kinase (AMPK), in these protective actions of metformin. The anti-adipogenic actions of
metformin were observed in multipotent C3H10T1/2 MSCs, in which metformin exerted reciprocal
control over the activities of Runx2 and the adipogenic transcription factor, PPARg, leading to sup-
pression of adipogenesis. These effects appeared to be independent of AMPK activation but rather
through the suppression of the mTOR/p70S6K signalling pathway. Basal AMPK and mTOR/p70S6K activity
did appear to be required for adipogenesis, as demonstrated by the use of the AMPK inhibitor, compound
C. This observation was further supported by using AMPK knockout mouse embryo ﬁbroblasts (MEFs)
where adipogenesis, as assessed by reduced lipid accumulation and expression of the adipogeneic
transcription factor, C/EBPb, was found to display an absolute requirement for AMPK. Further activation
of AMPK in wild type MEFS, with either metformin or the AMPK-speciﬁc activator, A769662, was also
associated with suppression of adipogenesis. It appears, therefore, that basal AMPK activity is required
for adipogenesis and that metformin can inhibit adipogenesis through AMPK-dependent or -indepen-
dent mechanisms, depending on the cellular context.
© 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) is characterized by chronic
elevation of blood glucose levels because of systemic insulin resis-
tance. In addition to the reduction of insulin sensitivity in muscle,lding, Institute of Biological
h Campus, Heriot-Watt Uni-
).
rved.adipose tissue and the liver, it has been noted recently that people
with diabetes have increased risk of bone fractures (Janghorbani
et al., 2007,Kilpadi et al., 2014,Hothersall et al., 2013). Further-
more, the use of the thiazolidinedione (TZD) antidiabetic drug class,
which includes pioglitazone and rosiglitazone, has been shown to
increase the risk of bone fractures and secondary osteoporosis
(Lecka-Czernik, 2009,Grey et al., 2007,Schwartz et al., 2006).
TZDs act as agonists for the nuclear receptor peroxisome
proliferator-activated receptor gamma (PPARg) which is considered
to be the master regulator of fat cell development (adipogenesis)
(Tontonoz et al., 1994a). It is therefore thought that the detrimental
Fig. 1. Metformin and the AMPK-activator, A769662, suppress adipogenesis of CH3H10T1/2 MSCs.
A) Conﬂuent CH3H10T1/2 MSCs were induced to differentiate by addition 10% foetal calf serum (FCS) in the presence or absence of adipogenic IID medium (insulin, iso-
butylmethylxanthine and dexamethasone) and/or 10 mM pioglitazone (PIO), 500 mMmetformin or 100 mM A769662. After 5 days cells were ﬁxed with formalin and stained with Oil
Red O to detect neutral lipid accumulation. Representative micrographs from an experiment carried out on three separate occasions with similar results are shown.
B) Conﬂuent CH3H10T1/2 MSCs were induced to differentiate by addition 10% FCS in the presence or absence of IID medium and/or 500 mM metformin. Cell extracts were then
prepared after 5 days and immunoblotted with antibodies to perilipin, adiponectin and tubulin. Representative immunoblots from an experiment carried out on three separate
occasions with similar results are shown. Densitometric analysis of three immunoblots are shown as means ± SEM in the lower panel. Signiﬁcant increases relative to control are
indicated, *p < 0.05 and ***, p < 0.001.
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mesenchymal stem cells (MSCs) causing adipogenesis and, conse-
quently, suppressing bone development (osteogenesis) (Lecka-
Czernik et al., 2007,Shockley et al., 2009). Adipogenesis is regu-
lated by a temporally induced cascade involving PPARg and mem-
bers of the CCAAT/enhancer binding protein (C/EBP) transcription
factor family. In the initial stages of adipogenesis there is a transient
accumulation of C/EBPb and C/EBPd proteins, leading to a later
accumulation of C/EBPa and PPARg (Cao et al., 1991,Yeh et al., 1995).
C/EBPa and PPARg then promote gene expression characteristic of
an adipocyte phenotype and their expression remains elevated for
the life of the differentiated cell (Tontonoz et al., 1994b).
Metformin has been used clinically for the treatment of T2DM
since the 1960s and it is thought to function primarily through the
inhibition of hepatic gluconeogenesis (Cusi et al., 1996). Metformin
interferes with oxidative phosphorylation in the mitochondria by
inhibiting complex I in the electron transport chain, although the
exact mechanism of inhibition is not yet known (El-Mir et al.,
2000,Lantier et al., 2014). Metformin has also been shown to
stimulate osteogenic differentiation of MSCs towards osteoblasts
in vitro through the trans-activation of Runt-related transcription
factor 2 (Runx2), the key regulatory transcription factor for osteo-
genic differentiation (Jang et al., 2011) and, unlike TZDs, has been
shown to be associated with a reduced risk of fractures. Osteoblast
differentiation has been proposed to be dependent on the cellular
energy sensor AMP-activated protein kinase (AMPK), as the
expression of various osteogenic genes has been shown to be
inhibited by compound C, a chemical inhibitor of AMPK, and a
dominant negative form of AMPK (Banerjee et al., 1997). Further-
more, metformin stimulates AMPK activation through theinhibition of oxidative phosphorylation in hepatocytes (Zhou et al.,
2001).
AMPK is a heterotrimeric serine/threonine protein kinase that
acts as a cellular energy sensor due to its ability to be activated by
an increase in the AMP-ATP ratio, which leads to phosphorylation
of Thr172 on AMPKa by liver kinase B1 (LKB1) (Hardie, 2015,Woods
et al., 2003). AMPK can also be phosphorylated and activated at
Thr172 by calcium/calmodulin-dependent protein kinase kinase
(CaMKK) in a Ca2þ-dependent, AMP-independent manner (Hawley
et al., 2005). AMPK functions to inhibit ATP consuming pathways
and at the same time activate catabolic pathways to re-establish
cellular energy homeostasis. It has also been shown that AMPK
has an array of non-metabolic functions including promotion of
nitric oxide synthesis and numerous anti-inﬂammatory actions
(Jones et al., 2005,Reihill et al., 2007,Salminen et al., 2011,Morrow
et al., 2003, Salt and Palmer, 2012). Recently, it has been shown
that AMPK functions in cell differentiation by promoting osteogenic
differentiation while suppressing adipogenic differentiation
(Kanazawa et al., 2008,Vila-Bedmar et al., 2010), however, the role
of AMPK in cell commitment to differentiation remains unclear.
Therefore, the main aim of the current study is to determine the
effect of metformin on adipogenesis and, in particular, to under-
stand the role of the AMPK signalling pathway in these processes.
2. Materials and methods
2.1. Cell culture and induction of differentiation
AMPK a1/a2 knockout mouse embryonic ﬁbroblasts (MEFs),
C3H10T1/2 mouse mesenchymal stem cells (Clone 9; ATCC CCL-
Fig. 2. Effects of Metformin and the AMPK-activator, A769662, on early markers of differentiation in C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were stimulated for 5 days with 10 mM pioglitazone (PIO) or an adipogenic (IID) or osteogenic (AGD) cocktail, in the presence or absence of 500 mM
metformin or 100 mM A769662. Cell extracts were then prepared and immunoblotted with antibodies to PPARg, Runx2 and AMPK. The phosphorylation-dependent electrophoretic
mobility shift of Runx2 induced by AGD treatment is indicated (pRunx2). Representative immunoblots from an experiment carried out on three separate occasions with similar
results are shown.
B) Densitometric analysis of PPARg1 (upper panel) and PPARg2 (lower panel) levels relative to Runx2 are shown as means ± SEM. Signiﬁcant increases (*, p < 0.05) relative to control,
and signiﬁcant decreases relative to PIO-stimulated cells (#, p < 0.05), are indicated (n ¼ 3). Non-signiﬁcant changes are also indicated (ns).
C) Conﬂuent C3H10T1/2 cells were transfected with a PPARg (upper panel) and Runx2 (lower panel) luciferase gene reporter constructs, together with control Renilla luciferase
vector, and then stimulated for two days with 500 mM metformin or 100 mM A769662, in the presence or absence of 10 mM pioglitazone (PIO), adipogenic medium (IID) or
osteogenic medium (AGD). Cell extracts were then prepared and luciferase activities were measured using a dual luciferase reporter assay. Luciferase activities from three separate
experiments are shown as means ± SEM. Signiﬁcant increases in luciferase activity are indicated; *, p < 0.05, **, p < 0.01 and ***, p < 0.001, as are signiﬁcant decreases in activity, #,
p < 0.05 (n ¼ 3). Non signiﬁcance is also indicated (ns).
Fig. 3. The AMPK activator, A769662, but not metformin activates AMPK in
C3H10T1/2 cells.
Conﬂuent C3H10T1/2 cells were stimulated for the indicated times with 100 mM
A769662 or 500 mM metformin. Cell extracts were then prepared and immunoblotted
with antibodies towards the phosphorylated form of the AMPK substrate, ACC, or total
ACC, as indicated in the upper panel. Densitometric values were obtained from im-
munoblots from three separate experiments and are shown as means ± SEM in the line
graph in the lower panel. Signiﬁcant increases in pACC are indicated; **, p < 0.01
(n ¼ 3). Non signiﬁcance is also indicated (ns).
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(41965e039, Sigma-Aldrich Ltd, Gillingham, Dorset, UK) containing
10% (v/v) FCS, 2 mM glutamine, 100 U/mL penicillin and 100 mg/ml
streptomycin. To promote adipogenic differentiation, cells were
cultured in the standard media supplemented with either 10 mM
pioglitazone alone or in combination with 100 nM insulin, 500 mM
3-isobutyl-1-methylxanthine (IBMX) and 10 mM dexamethasone
(IID medium). For osteogenic differentiation, cells were cultured in
standard media supplemented with 284 mmol/L ascorbic acid,
10 mM b-glycerophosphate and 10 nM dexamethasone (AGD me-
dium). Differentiation media was changed every 3 days.2.2. Preparation of cell extracts
For the preparation of cell extracts from MEFs, the media was
aspirated and then cells were washed with ice cold PBS (137 mM
NaCl, 2.7 mMKCl,10mMNa2HPO4,1.8mMKH2PO4) and then either
100 ml of ice cold Triton-X100 lysis buffer (50 mM Tris-HCl pH 7.4,
50 mM NaF, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 250 mM
mannitol, 1% (v/v) triton X-100, 0.1 mM phenyl-
methanesulphonylﬂuoride (PMSF), 0.1 mM benzamidine, 5 mg/ml
soybean trypsin inhibitor,1 mMdithiothreitol (DTT),1 mMNa3VO4)
or 1 Laemmli-sample buffer (50 mM Tris-HCl pH 6.8, 2% (w/v)
SDS, 10% (v/v) glycerol, 0.1% (w/v) bromophenol blue, 50 mM DTT)
was added and then cells were harvested by scraping. Lysates
exracted with Triton-X100 were cleared by centrifugation
(24 100 g, for 5 min at 4 C) and the supernatant stored at20 C.
Samples lysed using 1 Laemmli-sample buffer were incubated in a
sonicating water bath at 60 C for 30 min prior to storage at20 C.C3H10T1/2 MSCs were harvested and nuclear extracts prepared
using the Nuclear Extraction kit from Active Motif, Belgium. Brieﬂy,
the media was aspirated and cells were harvested in ice-cold PBS
containing phosphatase inhibitors and centrifuged (200  g, for
5 min at 4 C) to obtain a cell pellet. The cell pellet was re-
suspended in complete lysis buffer containing 10 mM DTT and
phosphatase inhibitor cocktail and then centrifuged (14 000 g, for
10 min at 4 C) to obtain nuclear and supernatant fractions.
2.3. Western blotting
Protein samples were separated by SDS-PAGE and then trans-
ferred electrophoretically onto nitrocellulose membranes. Mem-
branes were blocked with 5% (w/v) Marvel milk powder in TBS
(20 mM Tris-HCl pH 7.5, 150 mM NaCl) for 1 h. Membranes were
then incubatedwith primary antibodies overnight at 4 C. Following
washes with TBST (TBS supplemented with 0.5% (v/v) Tween-20),
membranes were incubated with secondary antibodies for 1 h at
room temperature. Antibodies were diluted to the required con-
centration in 50% (v/v) Sea Block (Thermo Scientiﬁc) and 50% (v/v)
TBST. The primary antibodies included those purchased from Cell
Signalling Technologies (CST), Danvers, MA and included perilipin,
peroxisome proliferator-activated receptor gamma (PPARg; marker
for adipogenesis), Runt-related transcription factor 2 (Runx2;
marker for osteogenesis), phosphorylated-ACC (P-ACC (Ser79);
marker for AMPK activity), phosphorylated AMPKa (P- AMPKa
(Thr172); detects active AMPK) and phosphorylated-p70S6K (P-
p70S6K (Thr389); upstream regulator ofmTOR signalling). The rabbit
polyclonal adiponectin antibody was generated in house and the
tubulin antibody was bought from Abcam, Cambridge, UK. Anti-
bodies were detected using a LI-COR® Odyssey Infrared Imaging
systems and densitometric analysis was carried out using ImageJ
software (National Institute of Health, UK) software Version 1.47.
2.4. Oil Red O staining
Cells were incubated with adipogenic IID media in the presence
or absence of either 10 mMpioglitazone, 500 mMmetformin,100 mM
of the AMPK-activator, A769662, or 10 mM of the p70S6K-inhibitor,
rapamycin. Following differentiation, media was aspirated and cells
were ﬁxed to cell culture plates with 10% (v/v) neutral buffered
formalin for 30 min. The formalin was then aspirated and staining
was carried out with the addition of 0.3% (w/v) Oil Red O in iso-
propanol:water (60:40) for 5 min in room temperature. The Oil Red
O was then aspirated and wells washed with distilled water four
times. Imaging was carried out using a Zeiss Axiovert 25 micro-
scope with QImaging camera and supporting software.
2.5. AMPK activity assays
AMPK activity was determined in AMPK a1 plus AMPK a2
immuno-complexes through phosphorylation of the peptide
HMRSAMSGLHLVKRR [SAMS], as previously described (Morrow
et al., 2003). Brieﬂy, the AMPK immunoprecipitates were re-
suspended in 20 ml of HEPES Brij-35 buffer. Reaction mixtures
(20 ml) containing 5 ml of HEPES Brij-35 buffer, 5 ml of 1 mM SAMS
peptide in HEPES Brij-35 buffer, 5 ml of 1 mM AMP in HEPES Brij- 35
buffer and 5 ml of immunoprecipitate re-suspended inHEPES Brij-35
buffer, were prepared in 1.5mlmicrocentrifuge tubes on ice and the
reaction initiated by the addition of 5 ml of MgATP solution (1 mM
[g-32P] ATP, 250e500 c.p.m./pmol; 25 mM MgCl2 in HEPES Brij-35
buffer). Reaction mixtures were then incubated on a vibrating
platform in an air incubator at 30 C for 10 min. Assay mixtures
(15 ml) were spotted onto P81 phosphocellulose paper, and rinsed,
with gentle stirring to remove free ATP, for 5 min in 1% (v/v)
Fig. 4. The mTOR inhibitor, rapamycin, suppresses adipogenesis of C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were induced to differentiate by addition of 10% foetal calf serum (FCS) supplemented with adipogenic cocktail (IID), in the presence or absence of
the mTOR inhibitor, 10 mM rapamycin. After 5 days cells were ﬁxed with formalin and stained with Oil Red O to detect neutral lipid accumulation. Representative micrographs from
an experiment carried out on three separate occasions with similar results are shown.
B) Conﬂuent C3H10T1/2 cells were transfected with PPARg luciferase gene reporter construct, together with control Renilla luciferase vector and then stimulated for two days with
500 mM metformin or 10 mM rapamycin, in the presence or absence of IID. Cell extracts were then prepared and luciferase activity was measured using a dual luciferase reporter
assay. Luciferase activities from three separate experiments are shown as means ± SEM. Signiﬁcant increases in PPARg activity are indicated ***, p < 0.001, as are signiﬁcant
decreases in PPARg activity, #, p < 0.05, relative to IID-stimulated cells (n ¼ 3).
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on the phosphocellulose paper, before a ﬁnal 5minwashwith 1% (v/
v) phosphoric acid. A Beckman Multi-Purpose scintillation counter
LS 6500 was used to measure [32P]-labelled substrate. 3 ml of
scintillation ﬂuid was used per sample. Results were corrected for
radioactivity recovered in blank reactions lacking the SAMS peptide.
One unit of AMPK activity is that required to incorporate 1 nmol of
32P into the SAMS substrate peptide/min/mg protein.
2.6. Transient transfection and luciferase assay
C3H10T1/2 cells were transfected with the indicated plasmids in
6-well plates, with 1.125 mg/well PPRE (PPARg reporter, purchased
from Adgene) and 6xOSE reporter constructs (Runx2 reporter,
supplied by Jian Huang, Rush Medical Centre, Chicago, USA) using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) and then
treated with metformin, A769662 or rapamycin with and without
adipogenic differentiation media. Cells were then harvested 48 h
after transfection and assayed using the Luciferase reporter assaysystem (Promega, Madison, WI) according to manufacturer's in-
structions. As a transfection control, the Renilla plasmid 0.125 mg/
well was co-transfected in each transfection experiment, and the
luciferase activity was normalised to the Renilla activity.
2.7. Statistical analysis
All experiments were performed in triplicate and statistical
analysis was performed using Student's t-test or one-way ANOVA.
Results are expressed as mean ± standard error (SEM) and differ-
ences with p < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Metformin suppresses adipogenesis in C3H10T1/2 MSCs
It has been previously reported that treatment of preadipocyte
cell lines with AMPK activators inhibits their conversion to fat cells
(Lee et al., 2011, Habinowski and Witters, 2001). Paradoxically,
Fig. 5. Effects of rapamycin on AMPK and p70S6K activities in C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were stimulated for 5 days with IID, in the presence or absence of 500 mM metformin, 100 mM A769662, 10 mM rapamycin or the AMPK inhibitor,
10 mM compound C. Cell extracts were then prepared and immunoblotted with antibodies to phosphorylated ACC (Ser 79). Representative immunoblots from an experiment carried
out on three separate occasions with similar results are shown (upper panel). Densitometric values from 3 separate experiments are shown in the lower panel as means ± SEM.
Signiﬁcant increases relative to control are indicated, **, p < 0.01 and ***, p < 0.001 (n ¼ 3).
B) Conﬂuent CH310T1/2 cells were stimulated for 5 days with IID, in the presence or absence of 500 mMmetformin, 100 mM A769662, 10 mM compound C or 10 mM rapamycin. Cell
extracts were then prepared and immunoblotted with antibodies to phosphorylated p70S6K and total p70S6K. Representative immunoblots from an experiment carried out on three
separate occasions with similar results are shown in the upper panel. Densitometric analysis of mean ± SEM p70S6K phosphorylation from 3 separate experiments are shown in the
lower panel. Signiﬁcant increases (*, p < 0.05) relative to control, and signiﬁcant decreases relative to IID-stimulated cells (##, p < 0.01 and ###, p < 0.001), are indicated (n ¼ 3).
S.C. Chen et al. / Molecular and Cellular Endocrinology 440 (2017) 57e6862however, the widely used AMPK inhibitor, compound C, has also
been reported to inhibit adipogenesis of preadipocyte cell lines
(Nam et al., 2008). To try and address this apparent contradiction
and to further investigate the role of AMPK in the control of adi-
pogenesis of multipotent mesenchymal stem cells (MSCs), we
stimulated murine C3H10T1/2 MSCs with two known activators of
AMPK, metformin (500 mM) and A769662 (100 mM). Conﬂuent
cultures of C3H10T1/2 MSCs were treated for 5 days with medium
containing 10% foetal calf serum (FCS) supplemented with either an
insulin-containing, adipogenic medium (IID) and/or the anti-
diabetic drug, pioglitazone (PIO), which is a known agonist of the
adipogenic transcription factor, PPARg (Day and Bailey, 2007). Cells
were also incubated with 10% FCS alone, as negative control for
differentiation. After 5 days of treatment, cells were ﬁxed and then
stained with the neutral lipid stain, Oil Red O, to monitor lipid
accumulation, which is a widely used late marker of adipogenesis
(Fig. 1a). We found that treatment of cells with IID-containing
medium stimulated lipid accumulation in C3H10T1/2 MSCs, an
effect that was further enhanced by co-treatment of cells with PIO
(Fig. 1a). We also found that treatment of cells with either met-
formin or A769662 suppressed adipogenesis promoted by IID aloneor by a combination of IID plus PIO (Fig. 1A), with metformin being
amore effective inhibitor of lipid accumulation (Fig. 1A). The effects
of metformin on the suppression of adipogensis was conﬁrmed by
western blotting for two late markers of fat cell conversion, adi-
ponectin and perilipin, the expression of which were strongly
induced following IID treatment, but were suppressed in the
presence of metformin (Fig. 1B).
These results suggest that AMPK activators inhibit adipogenesis
of C3H10T1/2 MSCs. To further elucidate the mechanisms of action
of metformin and A769662 in these cells, we next treated cells with
10% FCS, supplemented with either IID or PIO, and measured the
protein expression levels of the transcription factor, PPARg, which
is a widely used early marker of adipogenesis (Fig. 2A and B). To
complement these experiments, we alsomeasured the activation of
PPARg transcriptional activity, by transfecting C3H10T1/2 cells with
PPARg-responsive luciferase reporter construct (Fig. 2C). We found
that treatment of cells for 5 days with 10% FCS in the presence of
either IID or PIO, induced a signiﬁcant increase in the two PPARg
splice variants, PPARg1 and PPARg2 (Fig. 2A and B), which corre-
lated with a signiﬁcant increase in PPARg transcriptional activity, as
determined by luciferase assay (Fig. 2c). In agreement with the Oil
Fig. 6. Compound C inhibits adipogenesis of C3H10T1/2 cells.
A) Conﬂuent CH3H10T1/2 cells were stimulated for 5 days with IID, in the presence or absence of the AMPK inhibitor, 10 mM compound C. Cell extracts were then prepared and
immunoblotted with antibodies to phosphorylated ACC (Ser 79). Representative immunoblots from an experiment carried out on three separate occasions with similar results are
shown (upper panel). Densitometric values from 3 separate experiments are shown in the lower panel as means ± SEM. Signiﬁcant decreases relative to control are indicated, #,
p < 0.05.
B) Conﬂuent CH3H10T1/2 cells were treated with 10% FCS supplemented with adipogenic cocktail (IID), in the presence or absence of the indicated concentrations of compound C.
After 5 days cells were ﬁxed with formalin and stained with Oil Red O to detect neutral lipid accumulation. Representative micrographs from an experiment carried out on three
separate occasions with similar results are shown.
C) Conﬂuent CH3H10T1/2 MSCs were induced to differentiate by addition 10% FCS in the presence or absence of IID medium and/or 10 mM Compound C or 10 mM rapamycin. Cell
extracts were then prepared after 5 days and immunoblotted with antibodies to perilipin and tubulin. Representative immunoblots from an experiment carried out on three
separate occasions with similar results are shown. Densitometric analysis of three immunoblots are shown as means ± SEM in the lower panel. Signiﬁcant increases relative to
control are indicated, ***p < 0.001 and signiﬁcant decreases with respect to IID-treated cells are indicated, ###, p < 0.001.
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cells with either metformin or A769662 effectively suppressed IID-
and PIO-stimulated increases in PPARg protein levels (Fig. 2A and
B), as well as IID- and PIO-stimulated PPARg activity (Fig. 2C), as
determined by gene reporter assays. Given that increases in PPARg
activity during the early stages of adipogenesis are necessary and
sufﬁcient to promote terminal fat cell development (Rosen and
Spiegelman, 2000), it appears that the ability of metformin and
A769662 to inhibit adipogenesis of C3H10T1/2 MSCs is linked to
their ability to suppresses increases in PPARg protein levels pro-
moted by treatment of cells with either IID or PIO. Moreover, giventhat the PPARg luciferase reporter assays were carried out after only
two days of differentiation, it appears that the suppressive actions
of metformin and A769662 occur at a very early stage of the adi-
pogenic process.
The control of differentiation of MSCs into fat and bone is
thought to be controlled through reciprocal regulation of PPARg
and the osteogenic transcription factor, Runx2 (Jeon et al.,
2003,Muruganandan et al., 2009), during the commitment stage
of differentiation. We therefore also examined Runx2 protein levels
(Fig. 2A and B) and activity (Fig. 2C). As a positive control for these
experiments, cells were incubated with 10% FCS supplemented
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induce Runx2 activity. We found that treatment of cells with 10%
FCS plus AGD for 5 days did not signiﬁcantly affect PPARg protein
levels (Fig. 2A and B) or activity (Fig. 2C). However, AGD treatment
alone did promote a noticeable phosphorylation band-shift of
Runx2 protein in treated cells (Fig. 2A), which correlated with an
increase in Runx2 activity, as determined by a Runx2 gene reporter
assay (Fig. 2C). Treatment with either metformin or A769662
signiﬁcantly increased Runx2 activity in C3H10T1/2 cells (Fig. 2C),
which did not correlate with an increase in AGD-promoted phos-
pho-Runx2 levels, as determined by band-shift (Fig. 2A). Since
osteogenesis and adipogenesis of MSCs are thought to be recipro-
cally regulated by the PPARg:Runx2 activation ratio (Chen et al.,
2016), we can conclude that the inhibitory actions of metformin
and A769662 on the adipogenesis of C3H10T1/2 MSCs can partly be
explained by reciprocal control of PPARg and Runx2 activity,
thereby favouring an osteogenic lineage. In addition, whereby the
actions of metformin and A769662 appear to be through the sup-
pression of adipogenic-dependent increases in PPARg expression,
the actions on Runx2 activity remain to be determined, but appear
to be independent of osteogenic-linked increases in Runx2 phos-
phorylation (Fig. 2A).3.2. Metformin suppresses adipogenesis in C3H10T1/2 MSCs
through the inhibition of the p70S6K signalling pathway and not
through the activation of AMPK
Bothmetformin and A769662 are reported to activate AMPK in a
variety of cell types (Zhou et al., 2001,Cool et al., 2006). Given the
inhibitory effects of these two compounds on early and late
markers of adipogenesis of C3H10T1/2MSCs (Figs.1 and 2), we next
tested their ability to activate AMPK in these cells. We did this by
measuring the phosphorylation of a known AMPK substrate, Ser 79
of acetyl coenzyme carboxylase (ACC), using phospho-speciﬁc an-
tibodies. Intriguingly, although A769662 provoked a robust and
rapid phosphorylation of ACC, which wasmaintained for up to 48 h,
metformin did not induce a signiﬁcant phosphorylation of ACC,
even after 48 h stimulation (Fig. 3). It is likely, therefore, that while
metformin is an effective inhibitor of the adipogenic differentiation
of C3H10T1/2 MSCs, in response to insulin-containing IID medium,
or activation of PPARg by PIO, this occurs through mechanisms that
are independent of AMPK activation. Recent work, however, has
shown that the control of osteogenesis is regulated through in-
teractions between PPARg and the mTOR/p70S6K signalling
pathway (Sun et al., 2013). Moreover, metformin has been shown to
inhibit the activation of the p70S6K pathway independently of
AMPK (Vazquez-Martin et al., 2009) in tumour cells and p70S6K has
been shown to be required for the growth hormone-dependent
adipose conversion of 3T3-F442A preadipocytes (Yarwood et al.,
1999). We therefore examined the role of the p70S6K pathway on
IID-induced adipogenesis of C3H10T1/2 cells by incubating cells
with the mTOR/p70S6K inhibitor, rapamycin. We found thatFig. 7. Metformin suppresses adipogenesis in MEFs.
A) Wild type and AMPK knockout (/) mouse embryonic ﬁbroblasts (MEFs) were treated w
also stimulated in the presence or absence of 1 mMmetformin or 100 mM A769662. Cells we
out on three separate occasions with similar results are shown.
B) Conﬂuent wild-type (upper panel) and AMPK/ (lower panel) MEFs were stimulated for
the presence or absence of 1 mM metformin or 100 mM A769662. Cell extracts were then
Representative immunoblots from experiments carried out on three separate occasions wit
C) Densitometric values taken at day 5 from the experiment carried out in Fig. 7B are shown
p < 0.01 and ***, p < 0.001. Signiﬁcant decreases relative to control are also indicated, #, p
D) Wild type MEFs were incubated with 1 mM metformin for the times indicated or with 10
with antibodies speciﬁc to the indicated proteins (upper panel). Results from densitometric
Signiﬁcant increases relative to t ¼ 0 are indicated, *, p < 0.05.incubation of differentiating cells with rapamycin dramatically
inhibited lipid accumulation associated with adipogenesis, as
determined by Oil Red O staining (Fig. 4A). Furthermore, rapamycin
also suppressed PPARg activity, as determined by gene reporter
assays, indicating that the mTOR/p70S6K pathway is required for
adipogenesis of C3H10T1/2 cells (Fig. 4B). We found that the effects
of rapamycin were speciﬁc to inhibition of mTOR/p70S6K, since
rapamycin treatment had no signiﬁcant effect of phospho-ACC
levels (Fig. 5A), indicating no effect on AMPK activity, but, rather,
signiﬁcantly inhibited phosphorylation of p70S6K on Thr 389
(Fig. 5B), which is the mTOR phosphorylation site critical for kinase
function (Saitoh et al., 2002). Importantly, both metformin and
A769662 also inhibited p70S6K phosphorylation (Fig. 5B), indicating
that suppression of adipogenesis of C3H10T1/2 MSCs by these
compounds may involve suppression of mTOR/p70S6K signalling at
early stages of commitment to differentiation.
Although we found that metformin inhibits mTOR/p70S6K sig-
nalling apparently independently of AMPK activation (Figs. 3 and
5A), this does not rule out a role for AMPK in the control of
p70S6K activation. In fact, it has been reported that AMPK inhibits
mTOR/p70S6K signalling, which is thought to underlie the actions of
metformin in a range of cellular contexts (Viollet et al.,
2012,Dowling et al., 2011). To determine whether the same rela-
tionship exists in C3H10T1/2 MSCs, we incubated cells with the
AMPK inhibitor, compound C, and determined its action on ACC
(Ser 79) and p70S6K (Thr 389) phosphorylation (Fig. 5A and B,
respectively). We found that compound C signiﬁcantly inhibited
both basal p70S6K (Thr 389; Fig. 5B) and ACC (Ser 79; Fig. 6A)
phosphorylation, suggesting that AMPK is linked to the activation
of mTOR/p70S6K signalling in these cells. We also found that 10 mM
compound C was able to inhibit adipogenesis of C3H10T1/2 cells
treated with IID, as determined by lipid accumulation (Fig. 6B) and
expression of the adipogeneic marker, perilipin (Fig. 6C), as well as
suppressing AMPK activation in the presence or absence of IID
(Fig. 6A). This suggests that basal levels of AMPK activity, perhaps
acting through the mTOR/p70S6K pathway (Fig. 5B), are important
for supporting adipose conversion of these cells.3.3. AMPK plays a dual role in regulating the adipogenesis of mouse
embryonal ﬁbroblasts (MEFs)
Our ﬁndings in C3H10T1/2 cells may provide the explanation for
the apparently conﬂicting, previous reports that both activation
AMPK and inhibition of AMPK block adipogenesis of 3T3-L1 pre-
adipocytes (Lee et al., 2011, Habinowski and Witters, 2001,Nam
et al., 2008). This has been suggested to be a result of AMPK
exerting differential control during the process of differentiation;
due to AMPK exerting different control at early time points versus
late time points. Instead, we hypothesise there is a threshold level
of AMPK activity required for adipogenesis, above which further
activation leads to a break on the process. Indeed, it is worth noting
that AMPK activity levels do not change signiﬁcantly duringith IID plus 10 mM pioglitazone (PIO) for 7 or 9 days as indicated. Wild type MEFs were
re then stained with Oil Red O. Representative micrographs from an experiment carried
the indicated times with 10 mM pioglitazone (PIO) plus (IID) and, for wild-type MEFs, in
prepared and immunoblotted with antibodies to C/EBPb and/or C/EBPd, as indicated.
h similar results are shown.
in the lower panel as means ± SEM. Signiﬁcant increases in expression are indicated, **,
< 0.05. Non-signiﬁcance is also indicated (ns).
0 mM A769662 for 30 min. Cells were then lysed and the lysates were immunoblotted
analysis of three separate immunoblots are shown in the lower panel as means ± SEM.
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C3H10T1/2 MSCs (unpublished observations) indicating that AMPK
activity must be kept under stringent control to allow the differ-
entiation of these cells. To investigate this relationship further, we
next examined the effects of metformin and A769662 and adipo-
genesis in wild type and AMPKa knockout (/) mouse embryonal
ﬁbroblasts (MEFs). We ﬁrst incubated wild type or AMPKa (/)
MEFs with 10% FCS, in the presence or absence of a combination of
adipogenic medium (IID) plus PIO, (Fig. 7A). Cells were then ﬁxed
and stained with Oil Red O at days 7 and 9, to monitor late-stage
triglyceride accumulation (Fig. 7A), and cell extracts were pre-
pared at days 1, 2 and 5, to detect levels of the early marker of
differentiation, the transcription factor C/EBPb, by western blotting
(Fig. 7B). We found that a combination of IID and PIO promoted a
large increase in lipid accumulation in wild type MEFs but not
AMPKa (/) MEFs, at days 7 and 9 (Fig. 7A). We also found that
after an initial increase in the expression of C/EBPb and C/EBPd at
day 1 in wild type MEFs, following IID and PIO treatment, levels fell
by day 5 but remained signiﬁcantly above basal (Fig. 7B). This was
not the case in AMPKa (/) MEFs, where C/EBPb levels returned to
basal by day 5 and remained at that level for up to 9 days of
treatment with differentiation medium (Fig. 7B). These results
suggest that a basal level of AMPKa is required for adipogenesis of
MEFs and exerts actions on both early and late markers of adipose
conversion. We next examine the effects of metformin and
A769662 on adipogenesis of MEFs in response to IID and PIO
treatment. We found that treatment of wild type MEFs with either
metformin or A769662 led to a reduction in lipid accumulation
(Fig. 7A) and C/EBPb protein levels (Fig. 7B), indicating that both
compounds are anti-adipogenic in these cells. We also found that
both metformin (1 mM) and A769662 (100 mM) signiﬁcantly
increased phosphorylation of ACC at (Ser 79; Fig. 7C), indicating
that they both exert their anti-adipogenic actions through the
activation of AMPK. Together with the results obtained from
CH310T1/2 MSCs this suggests that the role of AMPK in the control
of adipogensis is complex, suggesting both positive and negative
regulation that may depend on the cellular context. Moreover, the
anti-adipogenic actions of the anti-diabetic drug, metformin, may
be both AMPK-dependent and AMPK-independent, again depend-
ing on the cellular context.
4. Discussion
Previous work has shown that AMPK activation reduces adipo-
genesis in favour of osteogenesis in adipocyte-derived humanMSCs
(hMSCs) and bonemarrow-derivedMSCs (Kim et al., 2012,Lee et al.,
2014). In the present work, we found that the AMPK activators,
metformin and A769662, inhibited adipogenesis in murine
C3H10T1/2 MSCs and in wild type MEFs. Both AMPK activators
promoted a signiﬁcant activation of AMPK in wild type MEFs,
although, interestingly, we found that metformin, did not promote
AMPK activation in C3H10T1/2 cells (Fig. 3). Metformin has been
shown to activate AMPK in many different cell types; however a
requirement of AMPK for the therapeutic actions of metformin has
been questioned following genetic loss of function experiments
that demonstrated AMPK-independent mechanisms of action of
metformin during the inhibition of hepatic gluconeogenesis (Foretz
et al., 2010). The AMPK-independent action of metformin on the
inhibition of adipogenesis reported here might be due to cell type
speciﬁc effects or stage-speciﬁc effects during the differentiation
process. For example, most of the studies demonstrating an AMPK-
dependent action of metformin were conducted in more differen-
tiated cell lines, such as pre-osteoblasts (Jang et al., 2011, Kanazawa
et al., 2008,Cortizo et al., 2006), pre-adipocytes (Moreno-Navarrete
et al., 2011,Lee et al., 2012), myoblasts (Longnus et al.,2005,Kobashigawa et al., 2014,Fulco et al., 2008) and neuronal
mouse cell lines (Bang et al., 2014), instead of the more primitive
cell progenitors investigated here.
With regards to stage-speciﬁc effects, Pantovic et al. (Pantovic
et al., 2013) demonstrated that there is a coordinated time-
dependent activation of different signalling pathways during the
osteogenic differentiation of hMSCs, which is AMPK-dependent in
the early stages of differentiation followed by late stage activation
of the Akt/mTOR signalling pathway. Given the results presented
here, it could be argued that similar mechanisms might regulate
adipogenesis in murine MSCs. For example, we ﬁnd an overall
requirement for basal levels of AMPK activity for adipogenesis of
C3H10T1/2 cells, as demonstrated by the use of the AMPK inhibitor
compound C (Fig. 6B) and veriﬁed by the use of AMPK knockout
(/) MEFs (Fig. 7A). It should be noted, however, that AMPK ac-
tivity levels remain constant throughout the process of adipo-
genesis, as determined by AMPK activation assays (Supplementary
Fig. 1) and phosphorylation of ACC on Ser 79 (results not shown).
Despite this, the ability of metformin to inhibit adipogenesis was
found to be due to a reduction in the PPARg:Runx2 activation ratio
(Fig. 2C) and this was linked to the inhibition of mTOR/p70S6K
signalling (Fig. 4). This suggests that the ability of metformin to
control the commitment of MSCs to differentiate into either oste-
oblasts or adipocytes is governed at an early stage through the
inhibition of mTOR/p70S6K signalling. Moreover, wild type MEFs
were observed to accumulate lipid and increase expression of C/
EBPb in response to an adipogenic cocktail of IID plus PIO (Fig. 7).
These effects were blocked in AMPK (/) MEFs, which may
indicate that AMPK is required for efﬁcient, late stage lipid accu-
mulation or, since AMPK is involved in mitochondrial biogenesis,
altered mitochondrial function (Bergeron et al., 2001).
Overall, our work suggests that metformin exerts multiple ef-
fects to inhibit adipogenesis in different cell types. Therefore, the
overriding view that metformin exerts its effects on adipogenesis
simply by promoting AMPK activation may therefore need some
revision. In particular, the role of AMPK itself appears to be com-
plex, in that it appears to exert both positive and negative effects
during the adipogenic conversion of MEFs and C3H10T1/2 MSCs. In
conclusion, further investigation into how metformin suppresses
signalling through the mTOR/p70S6K pathway may lead to new
therapeutic intervention strategies to prevent unwanted bone
marrow adipogenesis associated with diseases, such as T2DM,
where bone health is impaired.
Acknowledgements
This work was funded by a research project grant from Tenovus
Scotland (grant number S13/15), awarded to SJY, IPS and SFA, a
Diabetes UK Equipment Grant (grant number BDA: 11/0004309),
awarded to SJY and IPS, and a British Heart Foundation Project
Grant (grant number PG/15/15/31316) awarded to SJY.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.mce.2016.11.011.
References
Banerjee, C., McCabe, L.R., Choi, J.Y., Hiebert, S.W., Stein, J.L., Stein, G.S., Lian, J.B.,
1997. Runt homology domain proteins in osteoblast differentiation: AML3/
CBFA1 is a major component of a bone-speciﬁc complex. J. Cell Biochem. 66,
1e8.
Bang, S., Chen, Y., Ahima, R.S., Kim, S.F., 2014. Convergence of IPMK and LKB1-AMPK
signaling pathways on metformin action. Mol. Endocrinol. 28, 1186e1193.
Bergeron, R., Ren, J.M., Cadman, K.S., Moore, I.K., Perret, P., Pypaert, M., Young, L.H.,
S.C. Chen et al. / Molecular and Cellular Endocrinology 440 (2017) 57e68 67Semenkovich, C.F., Shulman, G.I., 2001. Chronic activation of AMP kinase results
in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol.
Metab. 281, E1340eE1346.
Cao, Z., Umek, R.M., McKnight, S.L., 1991. Regulated expression of three C/EBP iso-
forms during adipose conversion of 3T3-L1 cells. Genes Dev. 5, 1538e1552.
Chen, Q., Shou, P., Zheng, C., Jiang, M., Cao, G., Yang, Q., Cao, J., Xie, N., Velletri, T.,
Zhang, X., Xu, C., Zhang, L., Yang, H., Hou, J., Wang, Y., Shi, Y., 2016. Fate decision
of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ.
0000023, 1128e1139.
Cool, B., Zinker, B., Chiou, W., Kiﬂe, L., Cao, N., Perham, M., Dickinson, R., Adler, A.,
Gagne, G., Iyengar, R., Zhao, G., Marsh, K., Kym, P., Jung, P., Camp, H.S., Frevert, E.,
2006. Identiﬁcation and characterization of a small molecule AMPK activator
that treats key components of type 2 diabetes and the metabolic syndrome. Cell
Metab. 3, 403e416.
Cortizo, A.M., Sedlinsky, C., McCarthy, A.D., Blanco, A., Schurman, L., 2006. Osteo-
genic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur.
J. Pharmacol. 536, 38e46.
Cusi, K., Consoli, A., DeFronzo, R.A., 1996. Metabolic effects of metformin on glucose
and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin.
Endocrinol. Metab. 81, 4059e4067.
Day, C., Bailey, C.J., 2007. Pioglitazone a2-enna, S.J. xPharm. In: Bylund, D.B. (Ed.),
The Comprehensive Pharmacology Reference. Elsevier, New York, pp. 1e4.
Dowling, R.J., Goodwin, P.J., Stambolic, V., 2011. Understanding the beneﬁt of met-
formin use in cancer treatment. BMC Med. 9, 33.
El-Mir, M.Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M., Leverve, X., 2000.
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the
respiratory chain complex I. J. Biol. Chem. 275, 223e228.
Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G.,
Sakamoto, K., Andreelli, F., Viollet, B., 2010. Metformin inhibits hepatic gluco-
neogenesis in mice independently of the LKB1/AMPK pathway via a decrease in
hepatic energy state. J. Clin. Invest. 120, 2355e2369.
Fulco, M., Cen, Y., Zhao, P., Hoffman, E.P., McBurney, M.W., Sauve, A.A., Sartorelli, V.,
2008. Glucose restriction inhibits skeletal myoblast differentiation by activating
SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell. 14, 661e673.
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., Reid, I.R., 2007.
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone
decreases bone formation and bone mineral density in healthy postmenopausal
women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92,
1305e1310.
Habinowski, S.A., Witters, L.A., 2001. The effects of AICAR on adipocyte differenti-
ation of 3T3-L1 cells. Biochem. Biophys. Res. Commun. 286, 852e856.
Hardie, D.G., 2015. AMPK: positive and negative regulation, and its role in whole-
body energy homeostasis. Curr. Opin. Cell Biol. 33, 1e7.
Hawley, S.A., Pan, D.A., Mustard, K.J., Ross, L., Bain, J., Edelman, A.M., Frenguelli, B.G.,
Hardie, D.G., 2005. Calmodulin-dependent protein kinase kinase-beta is an
alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2,
9e19.
Hothersall, E.J., Livingstone, S.J., Looker, H.C., Ahmed, S.F., Cleland, S., Leese, G.P.,
Lindsay, R.S., McKnight, J., Pearson, D., Philip, S., Wild, S.H., Colhoun, H.M., 2013.
Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national
registry study from Scotland. J. Bone Min. Res.
Jang, W.G., Kim, E.J., Bae, I.H., Lee, K.N., Kim, Y.D., Kim, D.K., Kim, S.H., Lee, C.H.,
Franceschi, R.T., Choi, H.S., Koh, J.T., 2011. Metformin induces osteoblast differ-
entiation via orphan nuclear receptor SHP-mediated transactivation of Runx2.
Bone 48, 885e893.
Janghorbani, M., Van Dam, R.M., Willett, W.C., Hu, F.B., 2007. Systematic review of
type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166,
495e505.
Jeon, M.J., Kim, J.A., Kwon, S.H., Kim, S.W., Park, K.S., Park, S.W., Kim, S.Y., Shin, C.S.,
2003. Activation of peroxisome proliferator-activated receptor-gamma inhibits
the Runx2-mediated transcription of osteocalcin in osteoblasts. J. Biol. Chem.
278, 23270e23277.
Jones, R.G., Plas, D.R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M.J.,
Thompson, C.B., 2005. AMP-activated protein kinase induces a p53-dependent
metabolic checkpoint. Mol. Cell. 18, 283e293.
Kanazawa, I., Yamaguchi, T., Yano, S., Yamauchi, M., Sugimoto, T., 2008. Metformin
enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells
via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem.
Biophys. Res. Commun. 375, 414e419.
Kilpadi, K.L., Eldabaje, R., Schmitz, J.E., Ehler, B., Thames, T.A., Joshi, A.P.,
Simmons 3rd, J.W., Michalek, J.E., Fajardo, R.J., 2014. Type 2 diabetes is associ-
ated with vertebral fractures in a sample of clinic- and hospital-based Latinos.
J. Immigr. Minor Health 16, 440e449.
Kim, E.K., Lim, S., Park, J.M., Seo, J.K., Kim, J.H., Kim, K.T., Ryu, S.H., Suh, P.G., 2012.
Human mesenchymal stem cell differentiation to the osteogenic or adipogenic
lineage is regulated by AMP-activated protein kinase. J. Cell Physiol. 227,
1680e1687.
Kobashigawa, L.C., Xu, Y.C., Padbury, J.F., Tseng, Y.T., Yano, N., 2014. Metformin
protects cardiomyocyte from doxorubicin induced cytotoxicity through an
AMP-activated protein kinase dependent signaling pathway: an in vitro study.
PLoS One 9, e104888.
Lantier, L., Fentz, J., Mounier, R., Leclerc, J., Treebak, J.T., Pehmoller, C., Sanz, N.,
Sakakibara, I., Saint-Amand, E., Rimbaud, S., Maire, P., Marette, A., Ventura-
Clapier, R., Ferry, A., Wojtaszewski, J.F., Foretz, M., Viollet, B., 2014. AMPK con-
trols exercise endurance, mitochondrial oxidative capacity, and skeletal muscleintegrity. Faseb J. 28, 3211e3224.
Lecka-Czernik, B., 2009. Bone as a target of type 2 diabetes treatment. Curr. Opin.
Investig. Drugs 10, 1085e1090.
Lecka-Czernik, B., Ackert-Bicknell, C., Adamo, M.L., Marmolejos, V., Churchill, G.A.,
Shockley, K.R., Reid, I.R., Grey, A., Rosen, C.J., 2007. Activation of peroxisome
proliferator-activated receptor gamma (PPARgamma) by rosiglitazone sup-
presses components of the insulin-like growth factor regulatory system in vitro
and in vivo. Endocrinology 148, 903e911.
Lee, H., Kang, R., Bae, S., Yoon, Y., 2011. AICAR, an activator of AMPK, inhibits adi-
pogenesis via the WNT/beta-catenin pathway in 3T3-L1 adipocytes. Int. J. Mol.
Med. 28, 65e71.
Lee, J.O., Lee, S.K., Kim, J.H., Kim, N., You, G.Y., Moon, J.W., Kim, S.J., Park, S.H.,
Kim, H.S., 2012. Metformin regulates glucose transporter 4 (GLUT4) trans-
location through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP
signaling in 3T3-L1 preadipocyte cells. J. Biol. Chem. 287, 44121e44129.
Lee, S., Cho, H.Y., Bui, H.T., Kang, D., 2014. The osteogenic or adipogenic lineage
commitment of human mesenchymal stem cells is determined by protein ki-
nase C delta. BMC Cell Biol. 15, 42.
Longnus, S.L., Segalen, C., Giudicelli, J., Sajan, M.P., Farese, R.V., Van Obberghen, E.,
2005. Insulin signalling downstream of protein kinase B is potentiated by
5'AMP-activated protein kinase in rat hearts in vivo. Diabetologia 48,
2591e2601.
Moreno-Navarrete, J.M., Ortega, F.J., Rodriguez-Hermosa, J.I., Sabater, M., Pardo, G.,
Ricart, W., Fernandez-Real, J.M., 2011. OCT1 Expression in adipocytes could
contribute to increased metformin action in obese subjects. Diabetes 60,
168e176.
Morrow, V.A., Foufelle, F., Connell, J.M., Petrie, J.R., Gould, G.W., Salt, I.P., 2003. Direct
activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in
human aortic endothelial cells. J. Biol. Chem. 278, 31629e31639.
Muruganandan, S., Roman, A.A., Sinal, C.J., 2009. Adipocyte differentiation of bone
marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic
program. Cell Mol. Life Sci. 66, 236e253.
Nam, M., Lee, W.H., Bae, E.J., Kim, S.G., 2008. Compound C inhibits clonal expansion
of preadipocytes by increasing p21 level irrespectively of AMPK inhibition.
Arch. Biochem. Biophys. 479, 74e81.
Pantovic, A., Krstic, A., Janjetovic, K., Kocic, J., Harhaji-Trajkovic, L., Bugarski, D.,
Trajkovic, V., 2013. Coordinated time-dependent modulation of AMPK/Akt/
mTOR signaling and autophagy controls osteogenic differentiation of human
mesenchymal stem cells. Bone 52, 524e531.
Reihill, J.A., Ewart, M.A., Hardie, D.G., Salt, I.P., 2007. AMP-activated protein kinase
mediates VEGF-stimulated endothelial NO production. Biochem. Biophys. Res.
Commun. 354, 1084e1088.
Rosen, E.D., Spiegelman, B.M., 2000. Molecular regulation of adipogenesis. Annu.
Rev. Cell Dev. Biol. 16, 145e171.
Saitoh, M., Pullen, N., Brennan, P., Cantrell, D., Dennis, P.B., Thomas, G., 2002.
Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target
of rapamycin phosphorylation site. J. Biol. Chem. 277, 20104e20112.
Salminen, A., Hyttinen, J.M., Kaarniranta, K., 2011. AMP-activated protein kinase
inhibits NF-kappaB signaling and inﬂammation: impact on healthspan and
lifespan. J. Mol. Med. Berl. 89, 667e676.
Salt, I.P., Palmer, T.M., 2012. Exploiting the anti-inﬂammatory effects of AMP-
activated protein kinase activation. Expert Opin. Investig. Drugs 21, 1155e1167.
Schwartz, A.V., Sellmeyer, D.E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B.,
Feingold, K.R., Strotmeyer, E.S., Resnick, H.E., Carbone, L., Beamer, B.A.,
Park, S.W., Lane, N.E., Harris, T.B., Cummings, S.R., 2006. Thiazolidinedione use
and bone loss in older diabetic adults. J. Clin. Endocrinol. Metab. 91, 3349e3354.
Shea, C.M., Edgar, C.M., Einhorn, T.A., Gerstenfeld, L.C., 2003. BMP treatment of
C3H10T1/2 mesenchymal stem cells induces both chondrogenesis and osteo-
genesis. J. Cell Biochem. 90, 1112e1127.
Shockley, K.R., Lazarenko, O.P., Czernik, P.J., Rosen, C.J., Churchill, G.A., Lecka-
Czernik, B., 2009. PPARgamma2 nuclear receptor controls multiple regulatory
pathways of osteoblast differentiation from marrow mesenchymal stem cells.
J. Cell Biochem. 106, 232e246.
Sun, H., Kim, J.K., Mortensen, R., Mutyaba, L.P., Hankenson, K.D., Krebsbach, P.H.,
2013. Osteoblast-targeted suppression of PPARgamma increases osteogenesis
through activation of mTOR signaling. Stem Cells 31, 2183e2192.
Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., Spiegelman, B.M., 1994. mPPAR
gamma 2: tissue-speciﬁc regulator of an adipocyte enhancer. Genes Dev. 8,
1224e1234.
Tontonoz, P., Hu, E., Spiegelman, B.M., 1994. Stimulation of adipogenesis in ﬁbro-
blasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79,
1147e1156.
Vazquez-Martin, A., Oliveras-Ferraros, C., Menendez, J.A., 2009. The antidiabetic
drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via in-
hibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell
Cycle 8, 88e96.
Vila-Bedmar, R., Lorenzo, M., Fernandez-Veledo, S., 2010. Adenosine 5'-mono-
phosphate-activated protein kinase-mammalian target of rapamycin cross talk
regulates brown adipocyte differentiation. Endocrinology 151, 980e992.
Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M., Andreelli, F., 2012.
Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond)
122, 253e270.
Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D.,
Schlattner, U., Wallimann, T., Carlson, M., Carling, D., 2003. LKB1 is the upstream
kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004e2008.
S.C. Chen et al. / Molecular and Cellular Endocrinology 440 (2017) 57e6868Yarwood, S.J., Sale, E.M., Sale, G.J., Houslay, M.D., Kilgour, E., Anderson, N.G., 1999.
Growth hormone-dependent differentiation of 3T3-F442A preadipocytes re-
quires Janus kinase/signal transducer and activator of transcription but not
mitogen-activated protein kinase or p70 S6 kinase signaling. J. Biol. Chem. 274,
8662e8668.
Yeh, W.C., Cao, Z., Classon, M., McKnight, S.L., 1995. Cascade regulation of terminaladipocyte differentiation by three members of the C/EBP family of leucine
zipper proteins. Genes Dev. 9, 168e181.
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J.,
Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., Moller, D.E., 2001.
Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin.
Invest. 108, 1167e1174.
